Community-based HCV screening: Knowledge and attitudes in a high risk urban population

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Norton, Brianna L ^a   Voils, Corrine I ^a   Timberlake, Sarah H ^a   Hecker, Emily J ^a   Goswami, Neela D ^a   Huffman, Kim M ^a   Landgraf, Anneka ^a   Naggie, Susanna ^a   Stout, Jason E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Attitudes; Behaviors; Health knowledge; Healthcare disparities; Hepatitis C; Patient education; Screening

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE;

ADULT; ARTICLE; ATTITUDE TO ILLNESS; COMMUNITY CARE; COMMUNITY PROGRAM; EDUCATIONAL STATUS; FEMALE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH EDUCATION; HEALTH SURVEY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HOMELESSNESS; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAL CARE; MIDDLE AGED; RISK ASSESSMENT; URBAN POPULATION; ADOLESCENT; AGED; ATTITUDE TO HEALTH; DRUG DEPENDENCE TREATMENT; HEALTH LITERACY; HEPACIVIRUS; ORGANIZATION AND MANAGEMENT; PROCEDURES; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COMMUNITY HEALTH SERVICES; FEMALE; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH LITERACY; HEPACIVIRUS; HEPATITIS C; HOMELESS PERSONS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NORTH CAROLINA; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES; URBAN POPULATION; YOUNG ADULT;

EID: 84896739528     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-74     Document Type: Article

References (40)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144(10):705-714. 10.7326/0003-4819-144-10-200605160-00004, 16702586.
2. US Department of Health and Human Services Combating the Silent Epidemic of Viral Hepatitis (Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis) 2011, US Department of Health and Human Services.
3. Verna EC, Brown RS. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006, 10(4):919-940. 10.1016/j.cld.2006.08.012, 17164125.
4. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010, 51(3):729-733. 10.1002/hep.23561, 20186842.
5. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006, 121(6):710-719. 1781913, 17278406.
6. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012, 156(4):271-278. 10.7326/0003-4819-156-4-201202210-00004, 22351712.
7. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138(2):513-521. 521 e511-516, 10.1053/j.gastro.2009.09.067, 19861128.
8. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011, 43(1):66-72. 10.1016/j.dld.2010.05.006, 20739252.
9. Centers for Disease Control and Prevention Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998, 47(RR-19):1-39. Centers for Disease Control and Prevention.
10. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012, 157(11):817-822. 10.7326/0003-4819-157-9-201211060-00529, 22910836.
11. Moyer VA. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2013,
12. Guerrero HJ GW, Fullmer C. A Novel Method of Reaching at-Risk Populations in Community Outreach Hepatitis Screening Programs 2008, San Fransisco, CA: AASLD.
13. Subiadur J, Harris JL, Rietmeijer CA. Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado. Public Health Rep 2007, 122(Suppl 2):12-17. 1831809, 17542447.
14. Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS. Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis 2001, 28(3):166-170. 10.1097/00007435-200103000-00008, 11289199.
15. Hadley J, Cunningham P. Availability of safety net providers and access to care of uninsured persons. Health Serv Res 2004, 39(5):1527-1546. 10.1111/j.1475-6773.2004.00302.x, 1361082, 15333121.
16. Gunn RA, Murray PJ, Brennan CH, Callahan DB, Alter MJ, Margolis HS. Evaluation of screening criteria to identify persons with hepatitis C virus infection among sexually transmitted disease clinic clients: results from the San Diego Viral Hepatitis Integration Project. Sex Transm Dis 2003, 30(4):340-344. 10.1097/00007435-200304000-00013, 12671556.
17. McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction 2001, 96(7):1007-1014. 10.1046/j.1360-0443.2001.967100710.x, 11440611.
18. Dieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML. Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics 2010, 51(2):149-156. 10.1016/S0033-3182(10)70675-7, 20332290.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374. 10.1002/hep.22759, 19330875.
20. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann Intern Med 2004, 140(5):370-381.
21. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997, 26(3 Suppl 1):122S-127S.
22. Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010, 53(4):616-623. 10.1016/j.jhep.2010.04.024, 20619475.
23. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368(20):1867-1877. 10.1056/NEJMoa1214854, 23607593.
24. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368(20):1878-1887. 10.1056/NEJMoa1214853, 23607594.
25. Hunt D, Pockros P. What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?. Curr Gastroenterol Rep 2013, 15(1):303.
26. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005, 40(Suppl 5):S339-345.
27. Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, Christiansen CL, Weinbaum CM, Southern WN. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis 2012, 44(6):497-503. 10.1016/j.dld.2011.12.014, 22342471.
28. Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Southern WN. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health 2012, 102(11):e115-121. 10.2105/AJPH.2012.300659, 22994166.
29. Litwin AH, Harris KA, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009, 37(1):32-40. 2692471, 19038524.
30. Proeschold-Bell RJ, Hoeppner B, Taylor B, Cohen S, Blouin R, Stringfield B, Muir AJ. An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. AIDS Behav 2011, 15(8):1721-1731. 10.1007/s10461-010-9870-1, 3160524, 21191643.
31. O'Brien S, Day C, Black E, Dolan K. Injecting drug users' understanding of hepatitis C. Addict Behav 2008, 33(12):1602-1605. 10.1016/j.addbeh.2008.07.005, 18762384.
32. Proeschold-Bell RJ, Blouin R, Reif S, Amana A, Rowland BJ, Lombard F, Stringfield B, Muir AJ. Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV. South Med J 2010, 103(7):635-641. 10.1097/SMJ.0b013e3181e1dde1, 20531062.
33. Krauskopf K, McGinn TG, Federman AD, Halm EA, Leventhal H, McGinn LK, Gardenier D, Oster A, Kronish IM. HIV and HCV health beliefs in an inner-city community. J Viral Hepat 2011, 18(11):785-791. 10.1111/j.1365-2893.2010.01383.x, 20950406.
34. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev 2012, 31(7):918-924. 10.1111/j.1465-3362.2012.00468.x, 22612899.
35. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008, 33(3):126-133. 10.1007/s10900-007-9083-3, 3800027, 18165889.
36. Surjadi M, Torruellas C, Ayala C, Yee HF, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci 2011, 56(1):213-219. 10.1007/s10620-010-1455-3, 3008930, 20972850.
37. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005, 40(Suppl 5):S313-320.
38. Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int 2013, 33(7):999-1007. 10.1111/liv.12150, 23509897.
39. Hawthorne K, Robles Y, Cannings-John R, Edwards AG. Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. Cochrane Database Syst Rev 2008, 3:CD006424.
40. Kiene SM, Barta WD. A brief individualized computer-delivered sexual risk reduction intervention increases HIV/AIDS preventive behavior. J Adolesc Health 2006, 39(3):404-410. 10.1016/j.jadohealth.2005.12.029, 16919803.